Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has now formulated a new psychedelic product designed to be infused with hot water prior to consumption.
On Wednesday, the company announced that its Numinus Bioscience division had developed a psilocybin-containing tea bag for use in clinical research.
Following the necessary studies and desired regulatory approvals, Numinus plan to use its mushroom tea to treat patients.
Read more: Numinus launches ketamine-assisted therapy in Toronto
Read more: Numinus reports sequential revenue dip of 5.7%
Each tea bag contains 25 milligrams of psilocybin and will be studied by upcoming psilocybin-assisted therapy practitioners receiving experiential training in a phase I trial. The company intends to use the tea bag in trial partnerships with Cedar Clinical Research, the clinical trial management division for Numinus.
“The tea bag is composed of Psilocybe cubensis, an internally developed strain BP-STAR, processed to produce a standardized dose of 25mg psilocybin on brewing as per the instructions on the package,” said Hilary Strath, communications director for Numinus.
The company also says that the product has been submitted to Health Canada to be included on the psilocybin supplier list for the Canadian Special Access Program.
“Numinus recognizes that solid therapeutic products, such as whole mushrooms or pills, might be unappealing or difficult to use by certain populations, such as some people receiving palliative care for serious illnesses,” said Dr. Paul Thielking, chief science officer of Numinus.
“This new product is part of our commitment to increasing accessibility to psychedelic-assisted therapies for those in need, while contributing to the growing research that suggests psilocybin use in combination with therapy may be highly effective for treating mental health disorders.”
